On Thursday, Shares of Linear Technology Corporation (NASDAQ:LLTC), lost -1.76% to $41.79.
The total volume traded on Thursday accounted for 8,968,300. The high and low price for the day was $41.96 and $40.49 respectively. The stock, as of recent close, has shown weekly upbeat performance of 7.1% which was maintained at -9.05% in this year.
Linear Technology Corporation, together with its auxiliaries, designs, manufactures, and markets a line of analog integrated circuits worldwide. The company offers amplifiers, high speed amplifiers, voltage regulators and references, interface circuits, data converters, battery stack monitors, silicon oscillators and Timer Blox, and phase locked loop synthesizers and clock distribution products.
Shares of CONSOL Energy Inc. (NYSE:CNX), inclined 2.56% to $11.60, during its last trading session.
CONE Midstream Partners, declared that it will release financial results for the third quarter of 2015 before market opening on Tuesday, November 3, 2015 and hold a conference call to discuss those results on the same day at 1:00 p.m. Eastern Time. The conference call will be publicly available via webcast on a live and replay basis.
Interested parties are invited to listen to the conference call, during which prepared remarks by John T. Lewis, Chairman and Chief Executive Officer, and other members of administration will be followed by a question and answer session. Participants who would like to ask questions during the conference call may join by phone. Individuals who intend to listen only are encouraged to join the conference via the Internet.
CONSOL Energy Inc., together with its auxiliaries, operates as an integrated energy company in the United States and internationally. The company operates through two divisions, Exploration and Production (E&P), and Coal.
Finally, AbbVie Inc (NYSE:ABBV), ended its last trade with 0.72% gain, and closed at $56.03.
AbbVie, will declare its third-quarter 2015 financial results on Friday, Oct. 30, 2015, before the market opens.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
